Test Price
2,800 AED✅ Home Collection Available
CRYAA Gene (Autosomal Recessive Congenital Cataract Type 1) Genetic Test | Price: 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test guidance with a DHA-licensed specialist for result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CRYAA Genetic Test sequences the entire coding region of the CRYAA gene to identify pathogenic variants causing autosomal recessive congenital cataract type 1 (CTRCT1). This test is essential for early diagnosis in newborns and infants presenting with bilateral dense cataracts, guiding timely surgical intervention and genetic counselling. A mandatory pre-test genetic counselling session is required to obtain a detailed three-generation pedigree chart and document clinical history. The test can be performed on whole blood, extracted DNA, or a single drop of blood on an FTA card (ensure the card is completely dry before shipment). No special dietary or medication restrictions; inform the phlebotomist of any anticoagulant therapy.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative (Standard Single-Gene Sequencing) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity; full coding region + flanking intronic sites covered | 95–98% sensitivity; may miss deep intronic mutations |
| Method | Next-Generation Sequencing (NGS) with Sanger confirmation of pathogenic variants | Sanger sequencing only (lower throughput, longer TAT for full gene) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Sample Type | Whole Blood, Extracted DNA, or FTA Card | Whole Blood only |
Physician Insight & Safety Protocols
"As a DHA-licensed Consultant Medical Geneticist, I emphasize that this genetic test is a powerful diagnostic tool, but it must be interpreted in the full clinical context. A positive result confirms the molecular diagnosis, enabling planning for cataract extraction and long-term ophthalmic care, while a negative result does not exclude the condition if other genetic or environmental causes exist. Never make therapeutic decisions solely based on this report; always correlate with clinical findings."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This test does not provide information on drug efficacy or therapeutic management. Any changes to your child’s treatment plan must be supervised by the treating ophthalmologist.
Safety Exclusion Criteria
Exclusion Criteria
- Patient must not have undergone blood transfusion within the last 3 weeks (may affect genetic material purity).
- Do not collect sample if the child has an active severe infection or sepsis.
- Not appropriate for prenatal samples unless specifically ordered as part of a comprehensive prenatal genetic panel.
Emergency Red Flags (Seek Immediate Medical Attention)
- If your child develops sudden eye redness, pain, or vision loss after the test, visit the emergency room immediately.
- Any adverse reaction to blood draw (fainting, severe bleeding) requires urgent care.
Patient FAQ & Clinical Guidance
1. What is the purpose of the CRYAA gene test?
The CRYAA NGS test identifies mutations in the CRYAA gene responsible for autosomal recessive congenital cataract type 1, confirming the diagnosis in infants with bilateral cataracts at birth.
2. How is the sample collected and is it painful?
A certified phlebotomist collects a small amount of blood (or a drop on an FTA card) via a near-painless finger prick or venipuncture; the procedure takes less than 5 minutes and is safe even for newborns.
3. How soon will I get the results and what do they mean?
Results are available within 3–4 weeks; a positive report indicates detection of a disease-causing variant, while a negative result may require further evaluation by a geneticist or ophthalmologist for alternative diagnoses.
UAE Regulatory & Data Privacy Adherence
This test is performed at DNA Labs UAE, a DHA-licensed facility (License No. 1143). All genetic data processing complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information is encrypted, access-controlled, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | CRYAA Gene (Autosomal Recessive Congenital Cataract Type 1) Genetic Test |
| Price (AED) | 2800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | Q12.0 |
| LOINC Code | 81126-0 |
| DHA Facility License & Laboratory Address | DHA License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians